Revolutionizing
LST therapy that shrinks and
softens sclera to restore close vision
Our technology uses focused laser energy to reposition the ciliary body, effectively restoring the eye's natural ability to focus on near objects without surgery or implants.
Slit-lamp mounted
Hands-free delivery on standard ophthalmic equipment
No touch
Fully non-contact procedure — nothing enters the eye
Low-cost IR laser
Affordable infrared platform, easy for clinics to deploy
Pilot safety study - completed 2025
100%
of eyes showed reading improvemnt
9 out of 11
patients reached standard newsprint reading threshold
The business management team
-
30 yrs executive leadership in emerging tech
-
Summit Tech ophthalmic startup — $1B exit
-
Avedro ophthalmic startup — $500M exit
-
Board Member, Heru Inc.
John Frantzis
Chief Executive Officer
-
30 yrs executive leadership in emerging tech
-
4 private company sales; multiple M&A
-
1 successful IPO
-
Exits total > $1.5B · APAC & EMEA ops
Dan Cho
Chief Business Officer
-
20+ yrs executive leadership in emerging tech
-
Global eyecare experience (Optos, Avedro, Oyster Point)
-
2 successful IPO (LMAT, AVDR)
-
Avedro: $500M exit
Dave Iannetta
Chief Commercial Officer
William McLendon
Operations
-
35 yrs executive leadership in emerging tech
-
3 successful IPOs · 3 private sales
-
Multiple business acquisitions
-
Exits total > $2.3B
Bruce Garcia
Finance
-
25 yrs corporate finance & accounting
-
3 private company sales
-
Laser-vision launch experience
-
Exits total > $300M
Medical & science leadership
Satish Herekar
Chief Technology Officer
-
25 yrs invention & rapid pre-clinical testing
-
Expert in laser-tissue interaction & device development
-
Founder of SenoGen Inc.
James Boll
Chief Science & Clinical VP
-
SVP New Product Development at Cynosure
-
Clinical Research at Hologic
-
Cross-functional R&D and engineering lead
Ronald R. Krueger, MD
-
Leading presbyopia expert & clinical researcher
-
Extensive ophthalmic-device clinical-trial experience